Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

John A. Charlson MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
09/1989 - 05/1993 B.A., Biology, Luther College, Decorah, IA
09/1995 - 05/1999 M.D., University of Iowa College of Medicine, Iowa City, IA

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
07/1999 - 06/2002 Resident, Medicine, General Internal Medicine (GIM), Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
07/2005 - 06/2007 Fellow, Neoplastic Diseases, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
04/2013 Lean Healthcare Certificate Program, University of Michigan, Ann Arbor, MI
01/2016 - 04/2016 Advanced Training Program in Healthcare Delivery Improvement, Intermountain Healthcare, Salt Lake City, UT

FACULTY APPOINTMENTS:
07/2002 - 06/2003 Chief Resident and Instructor, Medicine, Medical College of Wisconsin, Milwaukee, WI
07/2003 - 06/2005 Assistant Professor and Hospitalist, Medicine, General Internal Medicine (GIM), Medical College of Wisconsin, Milwaukee, WI
07/2007 - 06/2015 Assistant Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
07/2015 - Present Associate Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
07/2002 - 06/2023 Resident Evaluation Committee, Medical College of Wisconsin, Milwaukee, WI
01/2007 - 01/2008 Internal Review Committee, Pediatric Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
03/2008 - 07/2013 Internal Medicine Resident Curriculum Committee

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
01/2004 - 06/2005 Patient Safety Committee, Froedtert Hospital, Milwaukee, WI
08/2009 - 06/2018 Cancer Center Process Improvement Committee
09/2010 - Present Froedtert Cancer Committee, Froedtert Hospital, Milwaukee, WI
01/2012 - Present Department of Medicine Quality Committee, Hem/Onc Division Representative, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
06/2012 - Present Pharmacy and Therapeutics, Oncology Subcommittee, Froedtert Cancer Center, Milwaukee, WI
01/2013 - Present EPIC Stakeholders Committee, Froedtert Cancer Center, Milwaukee, WI
07/2013 - 12/2017 Cancer Center Readmissions/Length of Stay Committee, Froedtert Cancer Center, Milwaukee, WI
12/2013 - 06/2016 Department of Medicine Nominating Committee, Medicine, Medical College of Wisconsin, Milwaukee, WI
04/2014 - 06/2016 Lab Utilization Committee, Froedtert Hospital/Medical College of Wisconsin, Milwaukee, WI
07/2014 - 06/2016 Palliative Care Steering Committee, Medical College of Wisconsin, Milwaukee, WI
03/2015 - 06/2018 Maintenance of Certification (MOC) Steering Committee, Medical College of Wisconsin, Milwaukee, WI
09/2017 - Present Credentialing Committee, member, Medical College of Wisconsin, Milwaukee, WI
07/2018 - 01/2023 Day Hospital Medical Director (0.05 FTE), Froedtert Hospital, Milwaukee, WI
07/2019 - 01/2023 Cancer Center 24 Hour Clinic Medical Director, Froedtert Hospital, Milwaukee, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:
10/2012 - Present Data Safety Monitoring Committee, Froedtert Cancer Center, Milwaukee, WI
02/2014 - Present Sarcoma DOT Research Co-chair, Froedtert Cancer Center, Milwaukee, WI
10/2020 - Present Sarcoma LAPS Committee liaison, Froedtert Cancer Center, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:
07/2002 - Present Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Ave., Milwaukee, WI 53226
07/2002 - 06/2005 Zablocki VA Medical Center, 5000 W. National Ave., Milwaukee, WI 53295

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Americal Board of Internal Medicine- Internal Medicine
09/2002
09/2012
American Board of Internal Medicine– Medical Oncology
02/2007
02/2027
   
Licensure
Number Issue DateExpiration
Wisconsin License
42947-020
10/31/2003
10/31/2025
    

AWARDS AND HONORS:
05/2004 Outstanding Performance Award, Primary Care Division, Clement Zablocki VA Medical Center, Milwaukee, WI
09/2004 Top Ten Teaching Award, Medical Students, 2003-4, Medical College of Wisconsin, Department of Medicine
09/2004 Top Ten Teaching Award, Residents, 2003-4, Medical College of Wisconsin, Department of Medicine
10/2006 Donald J. Schuenke Cancer Fellowship
12/2008 Top 20 Outpatient Physicians, Froedtert Hospital, Milwaukee, WI
09/2009 - Present Best Doctors, 2009-2023, yearly
01/2016 Vitality Award

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
10/2006 - Present American Society of Clinical Oncology
09/2009 - Present Connective Tissue Oncology Society

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
03/2019 - 03/2020 The Sarcoma Journal
Journal Review
PLOS One; Clinical Cancer Research; Journal of Clinical Oncology

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
09/2018 - 06/2020 Concept Review Committee, Sarcoma Alliance for Research through Collaboration (SARC)
01/2021 - Present Medical Advisory Board, Rein In Sarcoma

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Non-Peer Review
Title:
FORMA-2102-ONC-102: A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation
Source:
FORMA Therapeutics
Role & Effort:
Institutional PI
Dates:
05/20/2019 - Present
  
Title:
SPRINGWORKS-NIR-DT-301: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adults Patients With Progressing Desmoid Tumors (DTs) Aggressive Fibromatosis (AF)
Source:
SpringWorks Therapeutics
Role & Effort:
Institutional PI
Dates:
05/20/2019 - Present
  
Title:
DECIPHERA-DCC-2618-03-002: A Phase 3, Interventional, Randomized, Multicenter, Open-label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Source:
Deciphera Pharmaceuticals
Role & Effort:
Institutional PI
Dates:
06/26/2019 - Present
  
Title:
A Phase 2, Single-Arm Study of Abemaciclib for Treatment of Advanced Soft Tissue and Bone Sarcoma Identified as Having CDK Pathway Alteration
Source:
Eli Lilly and Company
Role & Effort:
Project PI
PI:
Charlson, John A MD
Dates:
10/07/2019 - Present
  
Title:
HUTCHISON-2015-012-00US1: A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid Tumors
Source:
Hutchison MediPharma
Role & Effort:
Institutional PI
Dates:
12/31/2019 - Present
  
Title:
A Phase II Study of Cabozantinib and Temozolomide in Patients with Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Source:
Northwestern University/City of Hope
Role & Effort:
Institutional PI
Dates:
07/06/2020 - Present
  
Title:
ADP-0055-001-MAGE-A4-SURPASS: A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
Source:
Adaptimmune Therapeutics
Role & Effort:
Institutional PI
Dates:
07/07/2020 - Present
  
Title:
ALLIANCE-A091902: Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
Source:
Alliance
Role & Effort:
Institutional PI
Dates:
03/05/2021 - Present
  
Pending
Non-Peer Review
Title:
COG-NRG-ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
Source:
NRG Oncology and Children’s Oncology Group
Role & Effort:
Institutional PI
Dates:
08/04/2015 - 01/27/2019
  
Prior
Non-Peer Review
Title:
“A Multicenter, Open-Label Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment”
Source:
Johnson & Johnson Pharmaceutical R&D – ET743-SAR-3002
Role & Effort:
Institutional PI
Dates:
02/01/2007 - 10/28/2015
  
Title:
TDM4370g: A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in Her-2 Positive Metastatic Breast Cancer
Source:
Genentech/TDM4370G
Role & Effort:
Institutional PI
Dates:
06/2009 - 12/2012
  
Title:
A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma.
Source:
Ziopharm/IPM3001
Role & Effort:
Institutional PI
Dates:
05/25/2011 - 06/01/2012
  
Title:
Adverse Bony Effects of Breast Cancer Therapies-R1
Source:
American Cancer Society
Role & Effort:
CO-PI
PI:
Neuner, Joan MD, MPH
Dates:
07/01/2011 - 06/30/2016
Direct Funds:
$920,000 (Oracle Project: 2207004)
  
Title:
Developing a Bilingual Measure of Health Numeracy for Use in Cancer Care-R2
Source:
American Cancer Society Pass Through from University of Pennsylvania
Role & Effort:
Co-Investigator
PI:
Neuner, Joan MD, MPH
Dates:
07/01/2011 - 09/30/2015
Direct Funds:
$207,659 (Oracle Project: 2207438)
  
Title:
A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with an Anthracycline and Ifosfamide - ET743-SAR-3007.
Source:
Janssen/ET743-SAR-3007
Role & Effort:
Institutional PI
Dates:
09/27/2011 - 10/09/2013
  
Title:
ALLIANCE-AO91102: Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Source:
Alliance
Role & Effort:
Institutional PI
Dates:
12/07/2012 - 12/31/2014
  
Title:
A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma.
Source:
Threshold/TH-CR-406/SARC021
Role & Effort:
Institutional PI
Dates:
01/11/2013 - 12/26/2013
  
Title:
Mechanisms Underlying SES Disparities in Breast Cancer Mortality
Source:
NIH/NCI
Role & Effort:
Co-Investigator
PI:
Nattinger, Ann B MD, MPH
Dates:
03/01/2013 - 02/28/2017
Direct Funds:
$1,159,887 (Oracle Project: 2207943, Award Number: R01 CA170945)
  
Title:
Aldoxorubicin-P3-STS-01: A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy
Source:
CytRx/CTYRX-P3-STS-01
Role & Effort:
Institutional PI
Dates:
07/14/2014 - 11/30/2015
  
Title:
(PQE3) A Statewide RCT to Reduce Use of Ineffective or Unproven Breast Cancer Care
Source:
NIH/NCI
Role & Effort:
Co-Investigator
PI:
Nattinger, Ann B MD, MPH
Dates:
09/01/2014 - 08/31/2019
Direct Funds:
$2,697,749 (Oracle Project: 2208807, Award Number: R01 CA190016)
  
Title:
ALLIANCE-A091105: A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Source:
Alliance
Role & Effort:
Institutional PI
Dates:
10/06/2014 - 12/01/2016
  
Title:
COG-AEWS1031/RTOG-1172: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma
Source:
Children’s Oncology Group
Role & Effort:
Institutional PI
Dates:
08/04/2015 - 01/27/2019
  
Title:
ALLIANCE-A091401: Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma
Source:
Alliance
Role & Effort:
Institutional PI
Dates:
03/16/2016 - 08/01/2019
  
Title:
Using a Symptom Heuristics iPad App to Improve Symptom Self-Management in Adolescents and Young Adults with Cancer: A Pilot Study
Source:
AHW Educ Res Immed
Role & Effort:
PI
PI:
Charlson, John A MD
Dates:
04/01/2016 - 03/31/2018
Direct Funds:
$47,307 (CTSI Pilot Grant, Oracle Project: 5520404)
  
Title:
LILLY-15B-MC-JGDL: A Phase 1b (Open Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel with or without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Source:
Eli Lilly and Company
Role & Effort:
Institutional PI
Dates:
06/24/2016 - 08/01/2018
  
Title:
ALLIANCE-A091304: A Phase/Randomized Phase II Study of MLN0128 vs Pazopanib in Patients with Locally Advanced/Unresectable or Metastatic Sarcoma
Source:
Alliance
Role & Effort:
Institutional PI
Dates:
01/17/2017 - 11/19/2018
  
Title:
TRACON-105SAR301: A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone In Patients With Advanced Angiosarcoma
Source:
Tracon Pharmaceuticals
Role & Effort:
Institutional PI
Dates:
11/29/2017 - 05/03/2019
  
Title:
BLUEPRINT-BLU-285-1303: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Source:
Blueprint Medicines Corporation
Role & Effort:
Institutional PI
Dates:
08/29/2018 - 04/02/2020
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
National
Lecture, Multi-disciplinary Management of Desmoid Tumors, Annual Musculoskeletal Oncology Symposium, Chicago, IL, 09/2019
Highlights of the Day Session: Sarcoma Highlights, SCO (American Society of Clinical Oncology) Annual Meeting, Virtual Meeting, 06/04/2021
“Sarcoma Chemotherapy Overview”, Rein In Sarcoma – Sarcoma Scholar Boot Camp, Virtual Meeting, Organizing site University of Minnesota, 09/08/2022
Sarcoma Tumor Board: Does Age Inflence Biology and Management? The Treatment of Sarcomas in Young Adults, American Society of Radiation Oncology Annual Meeting, San Antonio, TX, 10/24/2022
 
Regional
Poster presentation – Hospitalists Providing Clinical Continuing Education for Inpatient Medical Nurses, Midwest SGIM regional meeting, Chicago, IL, 10/01/2004
Lecture – Transfusion Medicine, Seventeenth Annual Update in Primary Care, Medical College of Wisconsin, Egg Harbor, WI, 10/08/2004
Lecture – Management of Soft Tissue Sarcoma, Gundersen Clinic, La Crosse, WI, 08/13/2009
Lecture – Breast Cancer for Primary Care Physicians, 22nd Annual Update in Primary Care, Medical College of Wisconsin, Egg Harbor, WI, 10/09/2009
Lecture – Primary Care for Cancer Patients, American College of Physicians annual meeting, Wisconsin Dells, WI, 09/11/2010
Lecture – Sarcoma Update, Medical Oncology, Advances in Hematology and Oncology, Green Bay, WI, 10/2012
Lecture, Sarcoma Update, Agnesian Healthcare, Fond du Lac, WI, 03/2016
Lecture, Sarcoma Update, Hem Onc Grand Rounds, St Vincent Hospital, Green Bay, WI, 04/2016
Lecture, Sarcoma Treatment Update, 8th Annual Advances in Hematology and Oncology Fall Symposium, Green Bay, WI, 10/2019
Updates in Sarcoma Treatment, Bellin Oncology Grand Rounds, Bellin Hospital, Green Bay, WI (Virtual Meeting), 03/30/2022
Updates in Sarcoma Treatment, 11th Annual Advances in Hematology and Oncology Fall Symposium, Green Bay, WI, 10/29/2022
 
Local
Lab Overutilization and Resident Education, MCW General Internal Medicine Division Meeting, Milwaukee, WI, 03/31/2004
42 y/o man with HIV and rash, Clinicopathologic Case Conference (CPC), Clement J. Zablocki VA Medical Center, Milwaukee, WI, 11/18/2004
Taking Care of Older Patients in Different Settings: A Physician Panel, Panel Discussion, Sponsored by MCW student chapters of ACP, AGS, 03/12/2007
Oncologic Emergencies, Emergency Medicine Grand Rounds, MCW Emergency Medicine Residency, 03/06/2008
Nutrition and Breast Cancer Risk, Women’s Health Event, St. Matthew’s Lutheran Church, Wauwatosa, WI, 01/31/2010
Long-Term Effects of Breast Cancer Treatment, Medicine Grand Rounds, MCW Department of Medicine, 02/26/2010
Lecture – Primary Care Followup after Breast Cancer Treatment, 41st Annual Winter Refresher Course for Family Medicine, Milwaukee, WI, 02/03/2011
Lecture – Long Term Effects of Cancer Treatment, 3rd, Annual Wisconsin Survivorship Forum, Milwaukee, WI, 06/2012
“Living with Sarcoma", survivor event (Assisted in planning, participated in physician Q&A panel), Crowne Plaza, Wauwatosa, WI, 04/2013
Sarcoma Program Overview, “Living with Sarcoma”, survivor event, Radisson Hotel, Wauwatosa, WI, 05/2014
Soft Tissue Sarcoma, Medical Oncology Perspective, MCW Department of Plastic Surgery Grand Rounds, Wauwatosa, WI, 10/2014
Chemotherapy for Sarcoma, Sarcoma Survivor Event, Milwaukee County Zoo, Milwaukee, WI, 04/2016
AYA Cancer Care, Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 04/2017
Using a Symptom Heuristics iPad App to Improve Symptom Self-Management in Adolescents and Young Adults with Cancer, CTSI Research Symposium Seminar, Medical College of Wisconsin, Milwaukee, WI, 11/19/2018
 

COMMITTEE SERVICE:
Medical College of Wisconsin
07/2002 - 06/2003 Resident Evaluation Committee, Medical College of Wisconsin
03/2008 - Present Liaison between our division and medicine residency, coordinate resident lecture series and Medicine Grand Rounds speakers, Internal Medicine Resident Curriculum Committee, Medical College of Wisconsin
12/2008 - Present Hematology/Oncology Fellowship Committee, Medical College of Wisconsin
Planning Committee, 8th Biennial MCW Breast Cancer Symposium, Medical College of Wisconsin
 
Hospital
01/2004 - 06/2005 Patient Safety Committee, Froedtert Hospital
01/2007 Internal Review Committee, Pediatric Hematology/Oncology Program
08/2009 I serve as the primary physician representative on this quality improvement working group, implementing efforts to improve quality of care in the cancer center, Cancer Center Working Group Committee, Froedtert Hospital
09/2010 - Present Froedtert Cancer Committee, Froedtert Hospital
 

MCW TEACHING ACTIVITIES:
Medical Student Education
07/2002 - 06/2005 JMS Bedside Rounds, ward attending teaching
01/2003 - 05/2003 M1 Interviewing Course
03/2003 - 06/2008 Introduction to Clinical Exam (ICE) Course preceptor
07/2004 - 06/2005 Lecturer, JMS Internal Medicine Core Lecture Series, Topic – Anemia
08/2008 - 09/2018 Coordinator and preceptor, M4 Oncology Outpatient Clinic experience
08/2008 - 09/2018 Course director and preceptor, M4 Oncology Inpatient Clinic elective rotation
08/2008 - 09/2018 Course director and preceptor, M4 Oncology Consults Clinic elective rotation
07/2010 - Present Preceptor, M4 Ambulatory Immersion rotation
09/2010 - 09/2012 Pathology lecture – M2, Neoplasia Clinical Correlation
09/2012 - 12/2014 Preceptor, M1 Clinical Apprenticeship Students Trevor Bluemel (2012-13) and Anna Park (2013-14)
06/2013 - 06/2014 Preceptor, Medical Student Summer Quality Improvement Project, student Benjamin Morey. Breast clinic process improvement project
01/2016 - Present Preceptor, M1/M2 Clinical Apprentice Rotation
07/2019 - Present Faculty Advisor, medical student Oncology Interest Group
 
Resident and Fellow Education
07/2002 - 06/2003 Prepared monthly CPC conferences
07/2002 - 06/2003 Led morning report, prepared Noon Conference lectures
07/2003 - 06/2004 Resident continuity clinic preceptor
09/2003 - 06/2005 Lecturer, Internal Medicine 101 course, topic – Neurologic Examination
07/2004 - 06/2005 Director, Medicine Resident Procedures Rotation Coordinate procedural experiences for senior residents and implement curriculum dealing with issues related to bedside procedures
07/2005 - 06/2007 Monthly lecture to residents on inpatient Oncology service
07/2007 - Present Supervision and teaching as attending physician on Oncology consult and Oncology inpatient services
07/2007 - 06/2017 Lecturer, hematology/oncology fellow core curriculum Sarcoma, Localized Breast Cancer
08/2008 - 06/2017 Coordinator, hematology and oncology lecturers for Resident Academic Half Day
01/24/2012 - 01/2014 Psychosomatic Medicine Resident Lecture, annual Psychiatric aspects of cancer treatment
05/30/2013 ER Resident Core Curriculum lecture, Oncologic Emergencies
 
Continuing Medical Education
01/2004 - 06/2005 Hospitalist Nursing Education Series A colleague and I provide CME for nursing staff using case-based discussions of inpatient medicine topics
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
2018 - 2019 Trevor Argall, Research Advisor, Medical College of Wisconsin, GSTP1 Expression if Predictive of Sarcoma Response to Doxorubicin Based Chemotherapy. CTOS Annual Meeting 2019, Tokyo, Japan. Abstract 3256473, poster 150.
 
Clinical/Research Fellows
2020 - 2021 Ensi Voshtina, MCWAH Hem-Onc fellow, Research Advisor, Medical College of Wisconsin, Value and use of patient reported outcomes in sarcoma clinic through GetWell Loop app, ASCO Quality Care Symposium 2021. Abstract 347985.
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Fuller CK, Charlson JA, Dankle SK, Russell TJ. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol. 2010 Oct;63(4):e83-4.
2. Walters MP, Baynes K, Carrera GF, King DM, Wang D, Charlson J, Zambrano E. Adamantinoma with plasmacytoid features: expanding the spectrum of a diagnostically challenging entity. Ann Diagn Pathol. 2011 Oct;15(5):347-54.
3. Yao X, Hosenpud J, Chitambar CR, Charlson J, Cheng YC. A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer. J Cancer. 2012;3:145-51. PMCID: PMC3319980
4. Bedi M, King DM, Shivakoti M, Wang T, Zambrano EV, Charlson J, Hackbarth D, Neilson J, Whitfield R, Wang D. Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. Radiat Oncol. 2013 Mar 14;8:60. PMCID: PMC3621722
5. Bedi M, King DM, Charlson J, Whitfield R, Hackbarth DA, Zambrano EV, Wang D. Multimodality management of metastatic patients with soft tissue sarcomas may prolong survival. Am J Clin Oncol. 2014 Jun;37(3):272-7.
6. Bedi M, King DM, Whitfield R, Hackbarth DA, Neilson JC, Charlson JA, Wang D. The effect of smoking and major vein resection on post-therapy lymphedema in soft tissue sarcomas treated with neoadjuvant radiation and limb-salvage surgery. Am J Clin Oncol. 2015 Apr;38(2):184-8.
7. Nattinger AB, Pezzin LE, McGinley EL, Charlson JA, Yen TW, Neuner JM. Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. Springerplus. 2015;4(1):54. PMCID: PMC4320689
8. Bedi M, King DM, Saeed H, Tutton S, Charlson, JA, Hackbarth DA, Neilson JC. Localized Management of Soft Tissue Sarcoma Metastasis: A Review of a Multidisciplinary Approach. Can Res Frontiers. 2015;1(2):138. doi: 10.17980/2015.162
9. Neuner JM, Kamaraju S, Charlson JA, Wozniak EM, Smith EC, Biggers A, Smallwood AJ, Laud PW, Pezzin LE. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J Natl Cancer Inst. 2015 Aug;107(8). PMCID: PMC4580559
10. Bedi M, King DM, Hackbarth DA, Charlson JA, Baynes K, Neilson JC. Biopsies in the Community Lead to Postoperative Complications in Soft Tissue Sarcomas. Orthopedics. 2015 Sep;38(9):e753-9.
11. Nattinger AB, Pezzin LE, McGinley EL, Charlson JA, Yen TW, Neuner JM. Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. Springerplus. 2015;4:531. PMCID: PMC4577495
12. Miura JT, Charlson J, Gamblin TC, Eastwood D, Banerjee A, Johnston FM, Turaga KK. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. Eur J Surg Oncol. 2015 Oct;41(10):1386-92.
13. Klooster B, Rajeev R, Chrabaszcz S, Charlson J, Miura J, Bedi M, Gamblin TC, Johnston F, Turaga KK. Is long-term survival possible after margin-positive resection of retroperitoneal sarcoma (RPS)? J Surg Oncol. 2016 Jun;113(7):823-7.
14. D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13;403(10435):1460-1471. PMCID: PMC11419333
15. Rajeev R, Patel M, Jayakrishnan TT, Johnston FM, Bedi M, Charlson J, Turaga KK. Retroperitoneal solitary fibrous tumor: surgery as first line therapy. Clin Sarcoma Res. 2015;5:19. PMCID: PMC4551387
16. Miura JT, Charlson J, Gamblin TC, Eastwood D, Banerjee A, Johnston FM, Turaga KK. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. Eur J Surg Oncol 2015;41:1386. PMID:26251340.
17. Andreason M, Zhang C, Onitilo AA, Engel J, Ledesma WM, Ridolfi K, Kim K, Charlson JC, Wisinski KB, Tevaarwerk AJ. Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result. J Community Support Oncol. 2015 May;13(5):195-201. PMCID: PMC4511377
18. Biggers A, Shi Y, Charlson J, Smith EC, Smallwood AJ, Nattinger AB, Laud PW, Neuner JM. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. J Clin Oncol. 2016 Dec 20;34(36):4398-4404. PMCID: PMC5455308
19. Kashtan MA, Jayakrishnan TT, Rajeev R, Charlson JC, Johnston F, Clark Gamblin T, Turaga KK. Age-based disparities in treatment and outcomes of retroperitoneal rhabdomyosarcoma. Int J Clin Oncol. 2016 Jun;21(3):602-8.
20. Saeed H, King DM, Johnstone CA, Charlson JA, Hackbarth DA, Neilson JC, Bedi M. Preoperative Radiation Therapy Followed by Reexcision May Improve Local Control and Progression-Free Survival in Unplanned Excisions of Soft Tissue Sarcomas of the Extremity and Chest-Wall. Int J Surg Oncol. 2016;2016:5963167. PMCID: PMC5075633
21. Charlson J, Smith EC, Smallwood AJ, Laud PW, Neuner JM. Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors. J Natl Compr Canc Netw. 2016 Jul;14(7):875-80.
22. Charlson JA, McGinley EL, Nattinger AB, Neuner JM, Pezzin LE. Geographic Variation of Adjuvant Breast Cancer Therapy Initiation in the United States: Lessons From Medicare Part D. J Natl Compr Canc Netw. 2017 Dec;15(12):1509-1517.
23. Berger NG, Silva JP, Mogal H, Clarke CN, Bedi M, Charlson J, Christians KK, Tsai S, Gamblin TC. Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. Surgery. 2018 Feb;163(2):318-323.
24. Neuner JM, Shi Y, Kong AL, Kamaraju S, Smith EC, Smallwood AJ, Laud PW, Charlson JA. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. J Cancer Surviv. 2018 Apr;12(2):268-275.
25. Charlson J. Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. Curr Treat Options Oncol. 2018 Oct 25;19(12):65.
26. Wilkinson KH, Ethun CG, Hembrook M, Bedi M, Charlson J, Mogal H, Tsai S, Christians K, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Cullinan D, Fields RC, Weber S, Gamblin TC, Cardona K, Clarke CN. Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. J Surg Res. 2019 Jan;233:154-162.
27. Zarnecki KG, Kristianto J, Charlson J, Wilson B, Blank RD, Shaker JL. Diffuse osteosclerosis as a presentation of recurrent breast cancer: role of endothelin 1. Osteoporos Int. 2019 Aug;30(8):1699-1703.
28. Gannon NP, King DM, Ethun CG, Charlson J, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Votanopoulos K, Krasnick B, Fields RC, Cardona K, Bedi M. The role of radiation therapy and margin width in localized soft-tissue sarcoma: Analysis from the US Sarcoma Collaborative. J Surg Oncol. 2019 Sep;120(3):325-331.
29. Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 Aug 01;125(15):2610-2620. PMCID: PMC6771856
30. Squires MH, Ethun CG, Suarez-Kelly LP, Yu PY, Hughes TM, Shelby RD, Tran TB, Poultsides G, Charlson J, Gamblin TC, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Krasnick BA, Fields RC, Pollock RE, Grignol V, Cardona K, Howard JH. Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. J Surg Res. 2020 Jan;245:577-586.
31. Bedi M, Ethun CG, Charlson J, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Cullinan D, Fields RC, Cardona K, King DM. Is a Nomogram Able to Predict Postoperative Wound Complications in Localized Soft-tissue Sarcomas of the Extremity? Clin Orthop Relat Res. 2020 Mar;478(3):550-559. PMCID: PMC7145071
32. Thalji SZ, Tsai S, Gamblin TC, Clarke C, Christians K, Charlson J, Ethun CG, Poultsides G, Grignol VP, Roggin KK, Votanopoulos K, Fields RC, Abbott DE, Cardona K, Mogal H, other members of the US Sarcoma Collaborative. Outcomes of palliative-intent surgery in retroperitoneal sarcoma-Results from the US Sarcoma Collaborative. J Surg Oncol. 2020 Jun;121(7):1140-1147.
33. Macpherson CF, Stegenga K, Erickson JM, Linder LA, Newman AR, Elswick RK, Charlson J, Thomas S, Ameringer S. Adolescents and Young Adults with Cancer Using a Symptom Heuristics App: Provider Perceptions and Actions. J Adolesc Young Adult Oncol. 2020 Oct;9(5):579-585. PMCID: PMC7578178
34. Monga V, Skubitz KM, Maliske S, Mott SL, Dietz H, Hirbe AC, Van Tine BA, Oppelt P, Okuno S, Robinson S, O'Connor M, Seetharam M, Attia S, Charlson J, Agulnik M, Milhem M. A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. Cancers (Basel). 2020 Jul 11;12(7). PMCID: PMC7408640
35. Strong EA, Park SH, Ethun CG, Chow B, King D, Bedi M, Charlson J, Mogal H, Tsai S, Christians K, Tran TB, Poultsides G, Grignol V, Howard JH, Tseng J, Roggin KK, Chouliaras K, Votanopoulos K, Cullinan D, Fields RC, Gamblin TC, Cardona K, Clarke CN. High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. Surgery. 2020 Oct;168(4):760-767.
36. Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer. 2021 Aug;125(4):528-533. PMCID: PMC8368095
37. Ibrahim EH, Frank L, Baruah D, Arpinar VE, Nencka AS, Koch KM, Muftuler LT, Unal O, Stojanovska J, Rubenstein JC, Brown SA, Charlson J, Gore EM, Bergom C. Value CMR: Towards a Comprehensive, Rapid, Cost-Effective Cardiovascular Magnetic Resonance Imaging. Int J Biomed Imaging. 2021;2021:8851958. PMCID: PMC8147553
38. Ellison C, King DM, Neilson JC, Wooldridge A, Charlson JA, Hackbarth DA, Johnstone C, Bedi M. Preoperative Radiation Performed at a Nonsarcoma Center May Lead to Increased Wound Complications Following Resection in Patients With Soft Tissue Sarcomas. Am J Clin Oncol. 2021 Dec 01;44(12):619-623.
39. Bedi M, Singh R, Charlson JA, Kelly T, Johnstone C, Wooldridge A, Hackbarth DA, Moore N, Neilson JC, King DM. Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma. Adv Radiat Oncol. 2022;7(3):100850. PMCID: PMC9133395
40. Drom C, Schenheit K, Matzke M, Obeidat AZ, Molinaro J, Charlson J, Knight JM. Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report. Brain Behav Immun Health. 2023 Feb;27:100570. PMCID: PMC9791578
41. Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023 Mar 09;388(10):898-912. PMCID: PMC11225596
42. Wilcox T, Kleinertz A, Seadler BD, Joyce LD, Charlson J, Linsky PL. Transmediastinal primary pulmonary liposarcoma: Case report and review of management strategies. Rare Tumors. 2024;16:20363613241274230. PMCID: PMC11320392
 
Books, Chapters, and Reviews
1. Kochar's Handbood of Clinical Medicine for Students, 4th ed., 2009; contributing author for hematology and oncology chapters.
2. Sarcomas: Evidence-based Diagnosis and Management, 1st ed., 2020; senior author for Synovial Sarcoma chapter.
 
Editorials, Letters To Editor, Other
1. Charlson JA, ASCO Co-chair. MSTS, ASTRO, ASCO: The treatment of metastatic carcinoma and myeloma of the femur: Clinical practice guideline. Available at http://msts.org/view/download.php/education/mbd-cpg-amended. 2020.
 
Non-Refereed Journal Publications/Original Papers
1. Charlson J, Heinrich T, McCarron RM. How often should women be screened for breast cancer? Current Psychiatry. 2010 Oct;9(10):20-22.
 
Abstracts
1. Charlson JA, Hedin, T, Sparapani R, Guo C, Nattinger A. Early discontinuation of tamoxifen and aromatase inhibitors (AIs) by postmenopausal women with early-stage breast cancer. ASCO Annual Meeting 2010, abstract 524, poster discussion session.
2. Yao X, Hosenpud JR, Chitambar CR, Charlson JA, Cheng Y. Phase II study of combined docetaxel, epirubicin, and cyclophosphamide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer in a single institution. ASCO Annual Meeting 2010, abstract e11040.
3. Bedi M, King D, Hackbarth D, Charlson J, Whitfield R, Wang D. Prognostic variables for post-metastasis survival in patients with soft tissue sarcoma of the extremity and trunk. CTOS Annual Meeting 2011, poster 49.
4. Bedi M, King D, Zambrano E, Shivakoti M, Baynes K, Mautz A, DuBois M, Charlson J, Hackbarth D, Wang D. Estimation of prognostic variables for survival in patients with primary localized soft tissue sarcoma of extremity and trunk treated with neoadjuvant radiation of chemoradiation. CTOS Annual Meeting 2011, poster 132.
5. Ridolfi K, Zhang C, Onitilo A, Ledesma W, Andreason M, Engel J, Kim K, Wisinski KB, Tevaarwerk A, Charlson J. Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS). J Clin Oncol (Meeting Abstracts) May 2012, vol 30, no. 15, abstract 555.
6. Andreason M, Zhang C, Onitilo A, Charlson J, Ledesma W, Ridolfi K, Kim K, Wisinski K, Champeny T, Engel J, Millholland R, Dean J, Tevaarwerk A. Rural versus urban differences among patients (pts) with hormone-receptor positive (HR+) breast cancer (BC) and a 21-gene assay recurrence score (RS). ASCO Annual Meeting 2012, abstract 6063.
7. Ledesma WM, Onitilo A, Zhang C, Kim K, Andreason M, Charlson J, Ridolfi K, Engel J, Wisinski K, Millholland R, Dean J, Tevaarwerk A. Impact of exogenous female hormone use (EHU) on breast cancer (BC) recurrence as assessed by the 21-gene assay (Oncotype DX). ASCO Annual Meeting 2012, abstract 563.
8. Charlson JA, Smith E, Laud P, Smallwood A, Neuner J. Baseline bone mineral density testing among breast cancer patients prescribed aromatase inhibitors (AIs). J Clin Oncol 2013, vol 31 suppl; abstract 6642.
9. Biggers A, Neuner J, Smith E, Pezzin L, Laud P, Charlson J, Smallwood A. Medicare Part D low-income subsidy and disparities in breast cancer treatment. J Clin Oncol 2014. 32 supplement; abstract 6534.
10. Charlson J, Trabucco S, Ali S, Stephens P. Frequency of Cell-Cycle Gene Alterations in Bone Sarcomas. CTOS Annual Meeting 2017, abstract 2788006.
11. Bedi M, Mostafa M, Charlson J, Suster S, Johnstone C, Clarke C. Tumor Infilitrating Lymphocytes May Predict for Distant Metastasis in Soft Tissue Sarcomas. CTOS Annual Meeting 2018, Rome, Italy. Abstract 3042484.
12. Charlson J, Argall T, Szabo A. GSTP1 Expression if Predictive of Sarcoma Response to Doxorubicin Based Chemotherapy. CTOS Annual Meeting 2019, Tokyo, Japan. Abstract 3256473.
13. Voshtina E, Charlson JA. Value and use of patient reported outcomes in sarcoma clinic through GetWell Loop app. Journal of Clinical Oncology. 2021;39(28_suppl):179.